Send us your CV
Donostia - San Sebastián
Full-time
Permanent employee
Your mission
Do you want to join an innovative company in a top industry like Gene Therapy?
Your profile
We are always looking for passionate people to join our team and it could be you! Send us your CV and we will keep it for future opportunities.
About us
Our Goal is to provide the gold-standard DNA for AAV manufacture
TAAV started as a Joint Venture contract manufacturing organization formed by two leading biotechnology organizations within synthetic DNA and AAV manufacturing.
In February 2022, AskBio announced securing 100% ownership of TAAV Biomanufacturing Solutions, SL. TAAV will continue to manufacture AAV dbDNA™ both for third-party customers and AskBio’s internal product development pipeline.
In 2020 TAAV launched its state-of-the-art facility located in San Sebastian, Spain. The facility is comprised of four suites and additional support labs, that are specifically designed for the manufacture of high quality dbDNA™.
The company produces a synthetic DNA, dbDNA™, as an alternative to plasmid DNA for the manufacture of adeno-associated virus (AAV).
We view dbDNA™ as a disruptive technology in the DNA market creating a new industry standard for transfection-based AAV production. Our synthetic process leads to high yield at small scales, shortening manufacturing timelines, facilitating quicker production of AAV and increasing safety by eliminating residual bacterial sequences of plasmid DNA in the AAV product.
Discover our TAAV-produced dbDNA™ process for rAAV manufacturing.
TAAV started as a Joint Venture contract manufacturing organization formed by two leading biotechnology organizations within synthetic DNA and AAV manufacturing.
In February 2022, AskBio announced securing 100% ownership of TAAV Biomanufacturing Solutions, SL. TAAV will continue to manufacture AAV dbDNA™ both for third-party customers and AskBio’s internal product development pipeline.
In 2020 TAAV launched its state-of-the-art facility located in San Sebastian, Spain. The facility is comprised of four suites and additional support labs, that are specifically designed for the manufacture of high quality dbDNA™.
The company produces a synthetic DNA, dbDNA™, as an alternative to plasmid DNA for the manufacture of adeno-associated virus (AAV).
We view dbDNA™ as a disruptive technology in the DNA market creating a new industry standard for transfection-based AAV production. Our synthetic process leads to high yield at small scales, shortening manufacturing timelines, facilitating quicker production of AAV and increasing safety by eliminating residual bacterial sequences of plasmid DNA in the AAV product.
Discover our TAAV-produced dbDNA™ process for rAAV manufacturing.